The Role of Chromogranin A Assay in the Diagnosis of Pheochromocytomas

Author:

Mirică Alexandra, ,Bădărău Ioana A.,Papacocea Raluca I.,Scheau Cristian,Păun Sorin,Păun Diana L., , , , , ,

Abstract

Background: Pheochromocytomas (Pheo) are rare neuroendocrine tumors with a suggestive clinical picture, characterized by hypersecretion of catecholamines and other neuroendocrine biomarkers. Methods: The purpose of the study was to analyze the diagnostic features of Pheo and investigate the role played by different neuroendocrine and hormonal markers in diagnosing Pheo.The retrospective study involved a group of 69 patients diagnosed and treated with Pheo, who had both urinary and plasma catecholamines and neuroendocrine markers measured pre- and postoperatively. Results: After comparing pre- and postoperative hormonal parameters and neuroendocrine biomarker changes, numerous statistically significant findings were found. The analysis of the relationships between chromogranin A (CgA) levels, plasma and urine metanephrines, and normetanephrine and Pheo tumor size was included in the study. Additionally, we evaluated Cg A's diagnostic efficacy in comparison to plasma metanephrines, normetanephrine, and neuron-specific enolase (NSE) for Pheo. Conclusions: We obtained statistically significant data on pre- and postoperative differences for plasma and urinary catecholamines, CgA and NSE. Pheo tumor size is interdependent with serum levels of Cg A, plasma and urinary metanephrines, and normetanephrine. The best diagnostic power for Pheo was plasma normetanephrine, followed by plasma metanephrines and CgA.

Publisher

Asociatia Cadrelor Medicale din Spitalul Universitar de Urgenta Militar Central Dr. Carol Davila

Reference24 articles.

1. "1. Păun DL.; Mirica A. Pheochromocytomas and Paragangliomas: Genotype-Phenotype Correlations, in IntechOpen Pheochromocytoma, Paraganglioma and Neuroblastoma, 1st ed.; Cianci P., Restini E., Agrawal A., Eds.; Publisher London, United Kingdom, 2021; pp. 13-24.

2. 2. Marotta V, Zatelli MC, Sciammarella C, Ambrosio MR,Bondanelli M, Colao A, et al. Chromogranin A as circulating marker for diagnosis and management of neuroendocrine neoplasms: more flaws than fame, Endocr. Relat. Cancer. 2018; 25(1):R11-R29.doi: 10.1530/ERC17-0269.

3. 3. Mirica A, Badarau IA, Paun DL, et al. Clinical use of plasma chromogranin A in neuroendocrine tumors. Curr. Heal. Sci. J. 2015; vol. 41, no. 4, pp. 69-76.

4. 4. Mirica A, Badarau IA, Stefanescu AM, Mirica R, Paun SC, Paun DL, et al. The Role of Chromogranin A in Adrenal Tumors. Rev. Chim. (Bucharest 2018; vol. 69, no. 3, pp. 34-36.

5. 5. Pang Y, Liu Y, Pacak K, Yang C . Pheochromocytomas and paragangliomas: From genetic diversity to targeted therapies Cancers (Basel) 2019; vol. 11, no. 4, pp. 1-16.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3